Design and synthesis of novel antidiabetic agents

Archives of Pharmacal Research

Volumn 28, Issue 2, 2005, Pages 142-150

  Joon, Yeol Lee ^a   Park, Won Hui ^a   Cho, Min Kyoung ^a   Hyun, Jin Yun ^a   Chung, Byung Ho ^a   Youngmi, Kim Pak ^b   Hahn, Hoh Gyu ^c   Seung, Hoon Cheon ^a  

^a Chonnam National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

Antidiabetic agents; Malonate; Quercetin; Thiazolidinedione

Indexed keywords

ANTIDIABETIC AGENT; COMPLEMENTARY DNA; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; QUERCETIN;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DRUG DESIGN; FIBROBLAST; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; METABOLISM; MOUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMID; SYNTHESIS;

ANIMALS; CELLS, CULTURED; DNA, COMPLEMENTARY; DRUG DESIGN; FIBROBLASTS; GENETIC VECTORS; HYPOGLYCEMIC AGENTS; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PLASMIDS; PPAR GAMMA; QUERCETIN; TRANSFECTION;

EID: 21844433253     PISSN: 02536269     EISSN: 02536269     Source Type: Journal    
DOI: 10.1007/BF02977705     Document Type: Article

References (20)

1. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature, 414, 813-820 (2001).
2. Buckle, D. R., Cantello, B. C. C., Cawthorne, M. A., Coyle, P. J., Dean, D. K., Faller, A., Haigh, D., Hindley, R. M., Jefcott, L. J., Lister, C. A., Pinto, I. L., Rami, H. K., Smith, D. G., and Smith, S. A., Non-thiazolidinedione antihyperglycemic agents. 2: alpha-carbon substituted beta-phenylpropanoic acids. Bioorg. Med. Chem. Lett., 6, 2127-2130 (1996).
3. Cantello, B. C., Cawthorne, M. A., Haigh, D., Hindley, R. M., Smith, S. A., and Thurlby, P., [omega-(Heterocyclylamino) alkoxy]benzyl]-2,4- thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem., 37, 3977-3985 (1994).
4. Clark, D. A., Goldstein, S. W., Volkmann, R. A., and Eggler, J. F., Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents. J. Med. Chem., 34, 319-325 (1991).
5. DeFronzo, R. A., Bonadonna, R. C., and Ferrannini, E., Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 15, 318-368 (1992).
6. Fujita, T., Sugiyama, Y., Taketomi, S., Sohda, T., Kawamatsu, Y., Iwatsuka, H., and Suzuoki, Z., Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy) benzyl]-thiazolidine-2,4- dione (ADD-3878, U-63,287, ciglitazone), a new antidiabetic agent. Diabetes, 32, 804-810 (1983).
7. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., and Kliewer, S. A., An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 270, 12953-12956 (1995).
8. Marcus, A. O., Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. Diabetes Technol. Ther., 2, 101-110 (2000a).
9. Marcus, A. O., Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2. Diabetes Technol. Ther., 2, 275-285 (2000b).
10. Momose, Y., Meguro, K., Ikeda, H., Hatanka, C., Oi, S., and Sohda, T., Studies on antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem. Pharm. Bull., 39, 1440-1445 (1991).
11. Morral, N., Novel targets and therapeutic strategies for type 2 diabetes. Trends in endocrinology and metabolism, 14, 169-175 (2003).
12. Nuraliev, Iu. N. and Avezov, G. A., The efficacy of quercetin in alloxan diabetes. Eks. Klin. Farmakol., 55, 42-44 (1992).
13. Nuss, J. M. and Wagman, A. S., Recent advances in therapeutic approaches to type 2 diabetes, In Annual Reports in Medicinal Chemistry, Doherty, A. M., Ed., Academic Press, San Diego, CA, 35, 211-220 (2000).
14. Porte, D., Jr. and Schwartz, M. W., Diabetes complications: why is glucose potentially toxic? Science, 272, 699-700 (1996).
15. Satyanarayana, N. and Periasamy, M., Hydroboration or hydrogenation of alkenes with cobalt(II) chloride-sodium borohydride. Tetrahedron Lett., 25, 2501-2504 (1984).
16. Shetty, A. K., Rashmi, R., Rajan, M. G. R., Sambaiah, K., and Salimath, P. V., Nutrition Research (New York, NY, United States), 24, 373-381 (2004).
17. Shinkai, H., Onogi, S., Tanaka, M., Shibata, T., Iwao, M., Wakitani, K., and Uchida, I., Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents. J. Med. Chem., 41, 1927-1933 (1998).
18. Sohda, T., Mizuno, K., Imamiya, E., Sugiyama, Y., Fujita, T., and Kawamatsu, Y., Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives. Chem. Pharm. Bull., 30, 3580-3600 (1982).
19. Varma, S. D., Mizuno, A., and Kinoshita, J. H., Diabetic cataracts and flavonoids. Science, 195, 205-206 (1977).
20. Zimmet, P., Alberti, K. G. M. N., and Shaw, J., Global and societal implications of the diabetes epidemic. Nature, 414, 782 -787(2001).